Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199415367> ?p ?o ?g. }
- W3199415367 endingPage "629" @default.
- W3199415367 startingPage "616" @default.
- W3199415367 abstract "Immune suppression, exhaustion, and senescence are frequently seen throughout disease progression in acute myeloid leukemia (AML). We conducted a phase II study of high-dose cytarabine followed by pembrolizumab 200 mg i.v. on day 14 to examine whether PD-1 inhibition improves clinical responses in relapsed/refractory (R/R) AML. Overall responders could receive pembrolizumab maintenance up to 2 years. Among 37 patients enrolled, the overall response rate, composite complete remission (CRc) rate (primary endpoint), and median overall survival (OS) were 46%, 38%, and 11.1 months, respectively. Patients with refractory/early relapse and those receiving treatment as first salvage had encouraging outcomes (median OS, 13.2 and 11.3 months, respectively). Grade ≥3 immune-related adverse events were rare (14%) and self-limiting. Patients who achieved CRc had a higher frequency of progenitor exhausted CD8+ T cells expressing TCF-1 in the bone marrow prior to treatment. A multifaceted correlative approach of genomic, transcriptomic, and immunophenotypic profiling offers insights on molecular correlates of response and resistance to pembrolizumab.Immune-checkpoint blockade with pembrolizumab was tolerable and feasible after high-dose cytarabine in R/R AML, with encouraging clinical activity, particularly in refractory AML and those receiving treatment as first salvage regimen. Further study of pembrolizumab and other immune-checkpoint blockade strategies after cytotoxic chemotherapy is warranted in AML.See related commentary by Wei et al., p. 551. This article is highlighted in the In This Issue feature, p. 549." @default.
- W3199415367 created "2021-09-27" @default.
- W3199415367 creator A5001003479 @default.
- W3199415367 creator A5001098812 @default.
- W3199415367 creator A5005855096 @default.
- W3199415367 creator A5012395020 @default.
- W3199415367 creator A5014659694 @default.
- W3199415367 creator A5014676751 @default.
- W3199415367 creator A5017578509 @default.
- W3199415367 creator A5020894945 @default.
- W3199415367 creator A5025478600 @default.
- W3199415367 creator A5026510629 @default.
- W3199415367 creator A5028241860 @default.
- W3199415367 creator A5031561153 @default.
- W3199415367 creator A5035609080 @default.
- W3199415367 creator A5040303721 @default.
- W3199415367 creator A5042434251 @default.
- W3199415367 creator A5045281097 @default.
- W3199415367 creator A5046719320 @default.
- W3199415367 creator A5046806823 @default.
- W3199415367 creator A5068251484 @default.
- W3199415367 creator A5068544225 @default.
- W3199415367 creator A5069675791 @default.
- W3199415367 creator A5089694123 @default.
- W3199415367 date "2021-09-10" @default.
- W3199415367 modified "2023-10-11" @default.
- W3199415367 title "Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia" @default.
- W3199415367 cites W1488069418 @default.
- W3199415367 cites W1569756545 @default.
- W3199415367 cites W1597332663 @default.
- W3199415367 cites W174683914 @default.
- W3199415367 cites W1805359866 @default.
- W3199415367 cites W1982766090 @default.
- W3199415367 cites W2003579048 @default.
- W3199415367 cites W2040587086 @default.
- W3199415367 cites W2044224425 @default.
- W3199415367 cites W2050574097 @default.
- W3199415367 cites W2053627244 @default.
- W3199415367 cites W2053999133 @default.
- W3199415367 cites W2064308486 @default.
- W3199415367 cites W2089071559 @default.
- W3199415367 cites W2095012072 @default.
- W3199415367 cites W2095429270 @default.
- W3199415367 cites W2097192169 @default.
- W3199415367 cites W2107027906 @default.
- W3199415367 cites W2109611268 @default.
- W3199415367 cites W2116858301 @default.
- W3199415367 cites W2150480709 @default.
- W3199415367 cites W2159746057 @default.
- W3199415367 cites W2196159484 @default.
- W3199415367 cites W2214074259 @default.
- W3199415367 cites W2419140434 @default.
- W3199415367 cites W2466569700 @default.
- W3199415367 cites W2522337762 @default.
- W3199415367 cites W2618433578 @default.
- W3199415367 cites W2623089849 @default.
- W3199415367 cites W2806682325 @default.
- W3199415367 cites W2899030939 @default.
- W3199415367 cites W2899512090 @default.
- W3199415367 cites W2900410545 @default.
- W3199415367 cites W2903041954 @default.
- W3199415367 cites W2908581980 @default.
- W3199415367 cites W2909486828 @default.
- W3199415367 cites W2913558101 @default.
- W3199415367 cites W2938731144 @default.
- W3199415367 cites W2952775948 @default.
- W3199415367 cites W2965282989 @default.
- W3199415367 cites W2982353618 @default.
- W3199415367 cites W2994938720 @default.
- W3199415367 cites W3014292375 @default.
- W3199415367 cites W3030534638 @default.
- W3199415367 cites W3034640151 @default.
- W3199415367 cites W3041686036 @default.
- W3199415367 cites W3046214598 @default.
- W3199415367 cites W3047696352 @default.
- W3199415367 cites W3085208365 @default.
- W3199415367 cites W3092079205 @default.
- W3199415367 cites W3092341078 @default.
- W3199415367 cites W3093280293 @default.
- W3199415367 cites W4240098044 @default.
- W3199415367 doi "https://doi.org/10.1158/2643-3230.bcd-21-0070" @default.
- W3199415367 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8580622" @default.
- W3199415367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34778801" @default.
- W3199415367 hasPublicationYear "2021" @default.
- W3199415367 type Work @default.
- W3199415367 sameAs 3199415367 @default.
- W3199415367 citedByCount "31" @default.
- W3199415367 countsByYear W31994153672021 @default.
- W3199415367 countsByYear W31994153672022 @default.
- W3199415367 countsByYear W31994153672023 @default.
- W3199415367 crossrefType "journal-article" @default.
- W3199415367 hasAuthorship W3199415367A5001003479 @default.
- W3199415367 hasAuthorship W3199415367A5001098812 @default.
- W3199415367 hasAuthorship W3199415367A5005855096 @default.
- W3199415367 hasAuthorship W3199415367A5012395020 @default.
- W3199415367 hasAuthorship W3199415367A5014659694 @default.
- W3199415367 hasAuthorship W3199415367A5014676751 @default.
- W3199415367 hasAuthorship W3199415367A5017578509 @default.